<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129684</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1015</org_study_id>
    <nct_id>NCT04129684</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Effectiveness of Lactobacillus Reuteri for Periodontitis in a Chinese Population</brief_title>
  <official_title>A Randomized Single-blind, Parallel-arm Multi-center Clinical Trial to Evaluate the Effectiveness and Safety of Lactobacillus Reuteri for Treatment of Periodontitis in a Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China College of Stomatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Stomatology, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the efficacy of application of Lactobacillus Reuteri
      probiotics therapy on clinical improvement and on microbial shift in Chinese periodontitis
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periodontitis is a chronic inflammatory disease with a prevalence of 80% in Chinese adults,
      which is the main cause of tooth loss in adults. Periodontitis has also been demonstrated to
      be a risk factor for cardiovascular diseases, diabetes, and many other systemic diseases due
      to the host immune response elicited by periodontal pathogenic bacteria. In the last decade,
      probiotics therapy using Lactobacillus Reuteri has been applied for periodontitis patients in
      European countries. But no evidence has been provided for its effectiveness in a Chinese
      population. The aim of this study is to determine the efficacy of application of
      Lactobacillus Reuteri probiotics therapy on clinical improvement and on microbial shift in
      Chinese periodontitis patients. The influence of probiotics therapy on the host inflammatory
      cytokines levels in periodontitis patients with systemic diseases is also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pocket Probing Depth(PPD)</measure>
    <time_frame>at 3 months</time_frame>
    <description>Distance from the base of the periodontal pocket to the gingival margin(mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pocket Probing Depth</measure>
    <time_frame>at baseline, 1, 6 months</time_frame>
    <description>Distance from the base of the periodontal pocket to the gingival margin(mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Attachment Level</measure>
    <time_frame>at baseline, 1, 3 , 6 months</time_frame>
    <description>Distance from the base of the periodontal pocket to the CEJ or other fixed reference point (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Rate of Bleeding on Probing</measure>
    <time_frame>at baseline, 1, 3 , 6 months</time_frame>
    <description>To evaluate the inflammation and bleeding of gingiva (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of microorganisms in periodontal pockets</measure>
    <time_frame>at baseline, 1, 3 and 6 months</time_frame>
    <description>To observe the effectiveness of the probiotic on periodontal microorganisms: P. gingivalis; A. actinomycetemcomitans; T. forsythia; T. denticola; P. intermedia; L. reuteri (CFU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contents of inflammatory cytokines in periodontal pockets and blood</measure>
    <time_frame>at baseline, 1, 3 and 6 months</time_frame>
    <description>To observe the effectiveness of the probiotic on systemic and local inflammation: TNF-α; IL-1β; IL-6; IL-8; IL-10；INF-γ (Pg/ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SRP+BioGaia Prodentis oil drops and lozenges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SRP+subgingival delivery of placebo and placebo lozenges</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>subgingival delivery and lozenges</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 years of age

          2. Patients diagnosed with periodontitis clinically evident according to International
             Classification of Periodontal Diseases (2017) with periodontal probing depth ≥4mm,
             attachment loss of the most severe site in the adjacent area ≥3mm, and imaging bone
             loss more than 1/3 of the root length

          3. Natural teeth remaining in the mouth≥ 14

        Exclusion Criteria:

          1. Patients with any other systemic diseases which likely to alter the progression and
             course of periodontitis, except coronary disease, diabetes or hypertension.

          2. Patients with aggressive periodontitis.

          3. Patients who received any periodontal treatment in the past 6 months

          4. Pregnant or lactating women

          5. Patients who smoke

          6. Patients in the acute phase of an infectious disease

          7. Patients taking bisphosphonate mediation

          8. Patients who are on any probiotic, anticoagulants or antibiotic supplements for the
             past 3 months

          9. Patients allergic to lactate products

         10. Patients who are deemed uncooperative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanmin Wu, Doctor</last_name>
    <phone>+86 0571-87783607</phone>
    <email>wym731128@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang University</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanmin Wu, Doctor</last_name>
      <email>wym731128@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

